NeoDirect topical cream could be a life-changing treatment for PTSD

Biotech company Psycheceutical Bioscience Inc. has published observational data supporting the potential use of its proprietary ketamine topical cream NeuroDirect in the treatment of PTSD.

Observational data was collected from an outpa tient neurology and neuropsychiatry prac tice in a non-clinical setting, examining 100 patients 61 females and 39 males aged between 12 and 90 with long-term intractable depression, anxiety and other symptoms associated with PTSD.

Over 80% of patients reported that their thought processes were clearer and more focused and they were more aware of surroundings, as a result of the non-systemic topical cream being more effective at treating PTSD symptoms than current ketamine options using systemic delivery methods.

Patients responses were documented through objective measures such as the Hamilton Depression Scale and EEG tracings, showing:

NeuroDirect's design involves delivering compounds across the blood-brain barrier while bypassing the GI tract and liver, applying the topical cream on the back of the neck.

Chad Harman says that NeuroDirect ketamine has the potential to be a life-changing treatment option that provides profound benefits and relief for patients suffering from PTSD.

This novel delivery method could improve how psychedelic pharmaceutical drugs are developed, studied, and administered, according to the observational data. We are committed to bringing NeuroDirect ketamine through the formal steps necessary to achieve regulatory approvals to be able to make this revolutionary medicine available. The second edition of the Benzinga Psychedelics Capital Conference is coming to you!

The event will take place at the Fontainebleau Miami Beach Hotel in Florida on April 13, 2023. This is the place to get DEALS DONE, raise money, jumpstart M&A and meet investors and key partners.